Taltz and Zepbound meet primary and key secondary endpoints in PsA trial

The Together-PsA Phase 3b trial reported that concomitant Taltz and Zepbound met the primary endpoint and all key secondary endpoints at 36 weeks, showing statistically significant superiority to Taltz alone; greater reductions in psoriatic arthritis activity were seen as early as Week 4, before clinically meaningful weight loss.

The Together-PsA open-label Phase 3b clinical trial evaluated the concomitant use of Taltz and Zepbound compared with Taltz alone in adults with active psoriatic arthritis who were obese or overweight and had at least one additional weight-related comorbid condition. Results were presented in a late-breaking presentation at the 2026 American Academy of Dermatology Annual Meeting and were published in Arthritis & Rheumatology. At the 36-week primary endpoint, the combination of Taltz and Zepbound met the primary and all key secondary endpoints versus Taltz monotherapy. The study also reported earlier reductions in disease activity that preceded clinically meaningful weight loss. Key findings: - The trial met its primary endpoint at 36 weeks, with concomitant Taltz and Zepbound showing statistically significant superiority to Taltz alone. - Greater reductions in psoriatic arthritis disease activity were observed as early as Week 4 in the combination arm, before notable weight loss. - The combination increased the proportion of patients achieving Minimal Disease Activity and showed improvements in fatigue, physical function, and mental health–related quality of life. - Combination therapy was associated with improvements in inflammation and several cardiometabolic measures; BMI, body weight, systolic blood pressure, glucose, HbA1c, triglycerides, and total cholesterol showed nominally statistically significant changes versus monotherapy. - The study population consisted of adults with active psoriatic arthritis and obesity or overweight plus at least one weight-related comorbidity; the trial was open-label Phase 3b. Summary: The reported results indicate that adding Zepbound to Taltz produced broader clinical and cardiometabolic changes in the trial population. Findings were presented at the 2026 AAD Annual Meeting and published in a peer-reviewed journal. Undetermined at this time.